Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Phase Ib Study to Evaluate the Safety, Tolerability, And Pharmacokinetics of Gusacitinib in Subjects With Systemic Lupus Erythematosus (SLE)
Conditions
Interventions
Gusacitinib
Locations
1
United States
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Start Date
January 22, 2025
Primary Completion Date
January 22, 2025
Completion Date
January 23, 2025
Last Updated
March 13, 2025
NCT06875960
NCT06335979
NCT06647069
NCT07371468
NCT05843643
NCT06333483
Lead Sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions